Resverlogix Corp. (RVX) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Resverlogix Corp. (RVX) has a cash flow conversion efficiency ratio of 0.011x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CA$-972.79K ≈ $-703.70K USD) by net assets (CA$-90.31 Million ≈ $-65.33 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Resverlogix Corp. (RVX) defensive interval to measure how many days the company can operate on defensive assets alone.
Resverlogix Corp. - Cash Flow Conversion Efficiency Trend (2001–2025)
This chart illustrates how Resverlogix Corp.'s cash flow conversion efficiency has evolved over time, based on yearly financial data.
Resverlogix Corp. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Resverlogix Corp. ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Seker Finansal Kiralama AS
IS:SEKFK
|
0.184x |
|
Picogram Co. Ltd.
KQ:376180
|
-0.003x |
|
Hamama
TA:HMAM
|
0.187x |
|
First Hydrogen Corp
V:FHYD
|
0.032x |
|
Games Operators SA
WAR:GOP
|
0.024x |
|
ESS Tech Inc
NYSE:GWH
|
-1.425x |
|
Wing Yip Food Holdings Group Limited American Depositary Shares
NASDAQ:WYHG
|
0.026x |
|
111 Inc
NASDAQ:YI
|
0.139x |
Annual Cash Flow Conversion Efficiency for Resverlogix Corp. (2001–2025)
The table below shows the annual cash flow conversion efficiency of Resverlogix Corp. from 2001 to 2025. For the full company profile with market capitalisation and key ratios, see RVX market cap overview.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | CA$-88.80 Million ≈ $-64.24 Million |
CA$-3.73 Million ≈ $-2.69 Million |
0.042x | -11.77% |
| 2024-12-31 | CA$-81.73 Million ≈ $-59.13 Million |
CA$-3.89 Million ≈ $-2.81 Million |
0.048x | +35.51% |
| 2023-12-31 | CA$-74.47 Million ≈ $-53.87 Million |
CA$-2.61 Million ≈ $-1.89 Million |
0.035x | -41.26% |
| 2022-12-31 | CA$-59.28 Million ≈ $-42.88 Million |
CA$-3.54 Million ≈ $-2.56 Million |
0.060x | -55.43% |
| 2021-12-31 | CA$-59.87 Million ≈ $-43.31 Million |
CA$-8.02 Million ≈ $-5.80 Million |
0.134x | +121392.30% |
| 2020-12-31 | CA$-39.90 Million ≈ $-28.86 Million |
CA$-4.40K ≈ $-3.18K |
0.000x | -99.96% |
| 2019-12-31 | CA$-64.11 Million ≈ $-46.38 Million |
CA$-17.34 Million ≈ $-12.55 Million |
0.271x | +15.07% |
| 2018-12-31 | CA$-207.72 Million ≈ $-150.26 Million |
CA$-48.83 Million ≈ $-35.33 Million |
0.235x | -21.73% |
| 2017-12-31 | CA$-83.68 Million ≈ $-60.53 Million |
CA$-25.13 Million ≈ $-18.18 Million |
0.300x | +34.58% |
| 2016-12-31 | CA$-101.57 Million ≈ $-73.47 Million |
CA$-22.67 Million ≈ $-16.40 Million |
0.223x | -41.21% |
| 2015-12-31 | CA$-56.43 Million ≈ $-40.82 Million |
CA$-21.42 Million ≈ $-15.50 Million |
0.380x | +229.32% |
| 2014-12-31 | CA$-73.73 Million ≈ $-53.33 Million |
CA$-8.50 Million ≈ $-6.15 Million |
0.115x | -44.80% |
| 2013-12-31 | CA$-63.22 Million ≈ $-45.73 Million |
CA$-13.20 Million ≈ $-9.55 Million |
0.209x | -78.75% |
| 2012-12-31 | CA$-29.50 Million ≈ $-21.34 Million |
CA$-29.00 Million ≈ $-20.98 Million |
0.983x | +111.21% |
| 2011-12-31 | CA$2.74 Million ≈ $1.98 Million |
CA$-24.03 Million ≈ $-17.38 Million |
-8.766x | -95.92% |
| 2010-12-31 | CA$4.30 Million ≈ $3.11 Million |
CA$-19.24 Million ≈ $-13.92 Million |
-4.474x | -8.91% |
| 2009-12-31 | CA$4.46 Million ≈ $3.23 Million |
CA$-18.34 Million ≈ $-13.26 Million |
-4.108x | -266.55% |
| 2008-12-31 | CA$11.61 Million ≈ $8.40 Million |
CA$-13.01 Million ≈ $-9.41 Million |
-1.121x | +68.96% |
| 2007-12-31 | CA$5.44 Million ≈ $3.94 Million |
CA$-19.65 Million ≈ $-14.21 Million |
-3.611x | -137.13% |
| 2006-12-31 | CA$-1.02 Million ≈ $-738.42K |
CA$-9.93 Million ≈ $-7.18 Million |
9.724x | +1749.37% |
| 2005-12-31 | CA$7.48 Million ≈ $5.41 Million |
CA$-4.41 Million ≈ $-3.19 Million |
-0.590x | -166.26% |
| 2004-12-31 | CA$9.84 Million ≈ $7.12 Million |
CA$-2.18 Million ≈ $-1.58 Million |
-0.221x | +35.03% |
| 2003-12-31 | CA$2.60 Million ≈ $1.88 Million |
CA$-885.04K ≈ $-640.23K |
-0.341x | +29.20% |
| 2002-12-31 | CA$942.21K ≈ $681.58K |
CA$-453.56K ≈ $-328.10K |
-0.481x | -1038.52% |
| 2001-12-31 | CA$259.64K ≈ $187.82K |
CA$-10.98K ≈ $-7.94K |
-0.042x | -- |
About Resverlogix Corp.
Resverlogix Corp., a late-stage clinical biotechnology company, develops therapeutics for patients with chronic illnesses. Its lead drug is apabetalone (RVX-208), a small molecule selective bromodomain and extra-terminal inhibitor for patients with cardiovascular disease, chronic kidney disease, type 2 diabetes mellitus, low high-density lipoprotein, recent acute coronary syndrome, and post COVID… Read more